Review of sitagliptin phosphate: a novel treatment for type 2 diabetes
Sitagliptin (Januvia®, Merck Pharmaceuticals) is a dipeptidyl-peptidase inhibitor (DPP-4 inhibitor) that has recently been approved for the therapy of type 2 diabetes. Like other DPP-4 inhibitors its action is mediated by increasing levels of the incretin hormones glucagon-like peptide-1 (GLP-1) and...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2007
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1994027/ |
| id |
pubmed-1994027 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-19940272008-03-06 Review of sitagliptin phosphate: a novel treatment for type 2 diabetes Gallwitz, Baptist Review Sitagliptin (Januvia®, Merck Pharmaceuticals) is a dipeptidyl-peptidase inhibitor (DPP-4 inhibitor) that has recently been approved for the therapy of type 2 diabetes. Like other DPP-4 inhibitors its action is mediated by increasing levels of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). Sitagliptin is effective in lowering HbA1c, and fasting as well as postprandial glucose in monotherapy and in combination with other oral antidiabetic agents. It stimulates insulin secretion when hyperglycemia is present and inhibits glucagon secretion. In clinical studies it is weight neutral. This article gives an overview of the mechanism of action, the pharmacology, and the clinical efficacy and safety of sitagliptin in type 2 diabetes therapy. Dove Medical Press 2007-04 /pmc/articles/PMC1994027/ /pubmed/17580730 Text en © 2007 Dove Medical Press Limited. All rights reserved |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Gallwitz, Baptist |
| spellingShingle |
Gallwitz, Baptist Review of sitagliptin phosphate: a novel treatment for type 2 diabetes |
| author_facet |
Gallwitz, Baptist |
| author_sort |
Gallwitz, Baptist |
| title |
Review of sitagliptin phosphate: a novel treatment for type 2 diabetes |
| title_short |
Review of sitagliptin phosphate: a novel treatment for type 2 diabetes |
| title_full |
Review of sitagliptin phosphate: a novel treatment for type 2 diabetes |
| title_fullStr |
Review of sitagliptin phosphate: a novel treatment for type 2 diabetes |
| title_full_unstemmed |
Review of sitagliptin phosphate: a novel treatment for type 2 diabetes |
| title_sort |
review of sitagliptin phosphate: a novel treatment for type 2 diabetes |
| description |
Sitagliptin (Januvia®, Merck Pharmaceuticals) is a dipeptidyl-peptidase inhibitor (DPP-4 inhibitor) that has recently been approved for the therapy of type 2 diabetes. Like other DPP-4 inhibitors its action is mediated by increasing levels of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). Sitagliptin is effective in lowering HbA1c, and fasting as well as postprandial glucose in monotherapy and in combination with other oral antidiabetic agents. It stimulates insulin secretion when hyperglycemia is present and inhibits glucagon secretion. In clinical studies it is weight neutral. This article gives an overview of the mechanism of action, the pharmacology, and the clinical efficacy and safety of sitagliptin in type 2 diabetes therapy. |
| publisher |
Dove Medical Press |
| publishDate |
2007 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1994027/ |
| _version_ |
1611401466329694208 |